Clinical Feasibility of Monitoring Enoxaparin Anti-Xa Concentrations: Are We Getting It Right?

about

Clinical Feasibility of Monitoring Enoxaparin Anti-Xa Concentrations: Are We Getting It Right?

Item

http://www.wikidata.org/entity/Q50323429

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Clinical Feasibility of Monito ...... ions: Are We Getting It Right?

@en

Clinical Feasibility of Monito ...... ions: Are We Getting It Right?

@nl

type

Item

label

Clinical Feasibility of Monito ...... ions: Are We Getting It Right?

@en

Clinical Feasibility of Monito ...... ions: Are We Getting It Right?

@nl

prefLabel

Clinical Feasibility of Monito ...... ions: Are We Getting It Right?

@en

Clinical Feasibility of Monito ...... ions: Are We Getting It Right?

@nl

P1476

Clinical Feasibility of Monito ...... ions: Are We Getting It Right?

@en

P2093

Christopher D Miller

http://www.w3.org/2001/XMLSchema#string

Luke A Probst

http://www.w3.org/2001/XMLSchema#string

Robert W Seabury

http://www.w3.org/2001/XMLSchema#string

Wesley D Kufel

http://www.w3.org/2001/XMLSchema#string

William Darko

http://www.w3.org/2001/XMLSchema#string

P2860

Measuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical review

Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health

Prediction of creatinine clearance from serum creatinine

Dosing and monitoring of low-molecular-weight heparins in special populations.

Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.

Dose adjusting enoxaparin is necessary to achieve adequate venous thromboembolism prophylaxis in trauma patients.

Improving outcomes in therapeutic drug monitoring--a case history.

Clinical uses of low-molecular-weight heparins.

Human pharmacokinetics of low molecular weight heparins.

Effect of enoxaparin on peak and trough levels of antifactor Xa in patients with a creatinine clearance of less than 30 mL/min

P304

214-220

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1310/HPJ5203-214

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28439136

http://www.w3.org/2001/XMLSchema#string

P932

5396989

http://www.w3.org/2001/XMLSchema#string